Product How it works Pricing Blog FAQ About Contact
Anika Therapeutics

Anika Therapeutics (NASDAQ: ANIK) revenue

Anika Therapeutics reported revenue of $112.8m for fiscal 2025, 5.9% less than in fiscal 2024 ($119.9m). Since fiscal 2016 its revenue has grown by 9.1%, an average growth of 1.0% a year.

Anika Therapeutics's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2022, −23.0%.

Revenue, in millions of US dollars103.42016113.42017105.62018114.62019130.52020147.82021113.82022120.82023119.92024112.82025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$112.8m−5.9%−$11.1m−9.8%
2024$119.9m−0.7%−$5.1m−4.3%
2023$120.8m+6.1%$0.8m0.7%
2022$113.8m−23.0%$3.7m3.2%
2021$147.8m+13.3%$2.6m1.8%
2020$130.5m+13.8%−$28.3m−21.7%
2019$114.6m+8.6%$34.2m29.9%
2018$105.6m−6.9%$21.7m20.6%
2017$113.4m+9.7%$45.7m40.3%
2016$103.4m—$50.6m49.0%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Anika Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Anika Therapeutics ranks 279th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Anika Therapeutics, −5.9%.

RankCompanyRevenueRevenue growth
277thAgenus$114.2m10.4%
278thImmunitybio$113.3m668.3%
279thAnika Therapeutics$112.8m−5.9%
280thUroGen Pharma$109.8m21.4%
281stCentury Therapeutics$109.2m1,556.8%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Anika Therapeutics

How much revenue did Anika Therapeutics make in fiscal 2025?
Anika Therapeutics reported revenue of $112.8m for fiscal 2025, compared with $119.9m in fiscal 2024.
How much has the revenue of Anika Therapeutics grown?
Between fiscal 2016 and fiscal 2025 it went from $103.4m to $112.8m: 9.1% more, an average growth of 1.0% a year.
What was the best year for revenue at Anika Therapeutics?
Of its last 10 fiscal years, fiscal 2021, with $147.8m.
Where does Anika Therapeutics rank in its sector by revenue?
It ranks 279th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Anika Therapeutics come from?
From the annual report (Form 10-K) that Anika Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Anika Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Anika Therapeutics: the Anika Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.